2017 Press Releases

Neurocrine Announces Completion of Phase II Clinical Study of VMAT2 Inhibitor INGREZZA (valbenazine) in Adults with Tourette Syndrome Conference Call (Replay)
01/17/17 at 4:30 p.m. ET

Neurocrine Announces Completion of Phase II Clinical Study of VMAT2 Inhibitor INGREZZA (valbenazine) in Adults with Tourette Syndrome Conference Call
Tuesday, January 17, 2017 4:30 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Keyword Search
 
DateTitle 
01/17/17Neurocrine Announces Completion of Phase II Clinical Study of VMAT2 Inhibitor INGREZZA™ (valbenazine) in Adults with Tourette Syndrome
Eight Week Study Assessed Safety, Tolerability and Efficacy in 124 Adult Subjects Company to Host Conference Call and Webcast Today at 4:30pm ET/ 1:30pm PT SAN DIEGO, Jan. 17, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today the top-line results from the Company's Phase II T-Forward study of INGREZZA™ (valbenazine), a highly-selective small molecule Vesicular Monoamine Transporter 2 (VMAT2) inhibitor, in adults with Tourette syndrome. While the study showed ... 
Printer Friendly Version
01/06/17Neurocrine Biosciences Announces the Appointment of David-Alexandre Gros M.D. President and Chief Operating Officer
SAN DIEGO, Jan. 6, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX), a biotechnology company focused on neurological and endocrine related disorders, announced that David-Alexandre "DA" Gros M.D. has joined the executive management team as President and Chief Operating Officer.   "Neurocrine is very pleased to welcome Dr. Gros as our President and Chief Operating Officer as we move forward with our transformation into a commercial entity," said Kevin Gorman, Chief Executive Of... 
Printer Friendly Version
01/05/17Neurocrine Provides Update on FDA Advisory Committee for INGREZZA™ (valbenazine) for the Treatment of Tardive Dyskinesia
Company to Host Conference Call and Webcast Today, January 5th at 4:30pm ET / 1:30pm PT SAN DIEGO, Jan. 5, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that the U.S. Food and Drug Administration (FDA), after further review of the INGREZZA™ (valbenazine) New Drug Application (NDA), has decided to cancel the Psychopharmacologic Drugs Advisory Committee meeting which was originally scheduled for February 16, 2017. The FDA informed the Company that the Priority... 
Printer Friendly Version
01/03/17Neurocrine Biosciences to Present at the 35th Annual J.P. Morgan Healthcare Conference
Live Audio Webcast will be on January 9, 2017 SAN DIEGO, Jan. 3, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine Biosciences, will be presenting at the 35th Annual J.P. Morgan Healthcare Conference in San Francisco. The live presentation takes place on Monday, January 9 at 2:30pm PT (5:30pm ET).  The presentation will be webcast and may be accessed on the Company's website at http://www.neurocrine.com.   ... 
Printer Friendly Version